Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.

ABSTRACT:

Importance

Easy-to-administer antiviral treatments may be used to prevent progression from asymptomatic infection to COVID-19 and to reduce viral carriage.

Objective

Evaluate the efficacy and safety of subcutaneous casirivimab and imdevimab antibody combination (REGEN-COV) to prevent progression from early asymptomatic SARS-CoV-2 infection to COVID-19.

Design

Randomized, double-blind, placebo-controlled, phase 3 study that enrolled asymptomatic close contacts living with a SARS-CoV-2-infected household member (index case). Participants who were SARS-CoV-2 RT-qPCR-positive at baseline were included in the analysis reported here.

Setting

Multicenter trial conducted at 112 sites in the United States, Romania, and Moldova.

Participants

Asymptomatic individua

SUBMITTER: O'Brien MP 

PROVIDER: S-EPMC8219113 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature